Methotrexat Phares

Methotrexate, the active ingredient in Methotrexat Phares, is an antimetabolite presented as an injectable for intramuscular, intrathecal and intravenous use. It is employed in the management of autoimmune disorders and several malignant diseases, acting on rapidly dividing cells.

GNH USA supplies Methotrexat Phares as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across a range of autoimmune and oncologic conditions, targeting abnormal cell proliferation and immune activation. - Rheumatoid arthritis: reduces disease activity and joint inflammation. - Psoriasis: decreases skin plaque formation and severity. - Acute lymphoblastic leukemia: induces remission by inhibiting leukemic cell growth. - Non‑Hodgkin lymphoma: contributes to tumor control in combination regimens. - Gestational trophoblastic disease: promotes resolution of trophoblastic tissue. - Osteosarcoma: enhances chemotherapy effectiveness by limiting tumor cell replication.

Methotrexate may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Fatigue: general tiredness or weakness. - Oral ulcers: painful sores in the mouth. - Elevated liver enzymes: transient changes in liver function tests. - Low blood counts: mild neutropenia or anemia. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Severe hepatotoxicity: significant liver injury requiring monitoring. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Myelosuppression: profound neutropenia, thrombocytopenia, or pancytopenia. - Renal impairment: acute kidney injury. - Severe mucositis: extensive oral and gastrointestinal ulceration. - Neurotoxicity: seizures or encephalopathy, especially with intrathecal use.

Methotrexate requires careful monitoring and patient education to minimize risks. - Baseline testing: obtain liver function, renal function and complete blood count before initiation. - Monitoring: repeat laboratory assessments regularly during therapy. - Contraindications: avoid in pregnancy and lactation due to teratogenicity. - Drug interactions: review concomitant medications for potential additive toxicity. - Patient counseling: advise on folic acid supplementation and avoidance of alcohol. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors: may raise methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: enhances myelosuppression risk.

Moderate Interactions (Monitor Closely): - Penicillins: can reduce renal clearance of methotrexate. - Phenytoin: may lower methotrexate efficacy. - Live vaccines: risk of infection due to immunosuppression.